Among patients randomized to cinacalcet , a @ % reduction in FGF@ between baseline and week @ was associated with a nominally significant reduction in the primary composite end point ( relative hazard , @ ; @ % confidence interval , @-@ @ ) , cardiovascular mortality ( relative hazard , @ ; @ % confidence interval , @-@ @ ) , sudden cardiac death ( relative hazard , @ ; @ % confidence interval , @-@ @ ) , and heart failure ( relative hazard , @ ; @ % confidence interval , @-@ @ ) .